296 related articles for article (PubMed ID: 12808446)
1. How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration.
Zhou A; Huntington JA; Pannu NS; Carrell RW; Read RJ
Nat Struct Biol; 2003 Jul; 10(7):541-4. PubMed ID: 12808446
[TBL] [Abstract][Full Text] [Related]
2. Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin (Vn): mapping the binding sites on PAI-1 and Vn.
Schroeck F; Arroyo de Prada N; Sperl S; Schmitt M; Viktor M
Biol Chem; 2002; 383(7-8):1143-9. PubMed ID: 12437099
[TBL] [Abstract][Full Text] [Related]
3. Interactions of plasminogen activator inhibitor-1 with vitronectin involve an extensive binding surface and induce mutual conformational rearrangements.
Blouse GE; Dupont DM; Schar CR; Jensen JK; Minor KH; Anagli JY; Gårdsvoll H; Ploug M; Peterson CB; Andreasen PA
Biochemistry; 2009 Mar; 48(8):1723-35. PubMed ID: 19193026
[TBL] [Abstract][Full Text] [Related]
4. The reduced, denatured somatomedin B domain of vitronectin refolds into a stable, biologically active molecule.
Kamikubo Y; Kroon G; Curriden SA; Dyson HJ; Loskutoff DJ
Biochemistry; 2006 Mar; 45(10):3297-306. PubMed ID: 16519524
[TBL] [Abstract][Full Text] [Related]
5. Functional structure of the somatomedin B domain of vitronectin.
Zhou A
Protein Sci; 2007 Jul; 16(7):1502-8. PubMed ID: 17567740
[TBL] [Abstract][Full Text] [Related]
6. Plasminogen activator inhibitor-1 regulates cell adhesion by binding to the somatomedin B domain of vitronectin.
Deng G; Curriden SA; Hu G; Czekay RP; Loskutoff DJ
J Cell Physiol; 2001 Oct; 189(1):23-33. PubMed ID: 11573201
[TBL] [Abstract][Full Text] [Related]
7. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation.
Kjøller L; Kanse SM; Kirkegaard T; Rodenburg KW; Rønne E; Goodman SL; Preissner KT; Ossowski L; Andreasen PA
Exp Cell Res; 1997 May; 232(2):420-9. PubMed ID: 9168821
[TBL] [Abstract][Full Text] [Related]
8. Disulfide bonding arrangements in active forms of the somatomedin B domain of human vitronectin.
Kamikubo Y; De Guzman R; Kroon G; Curriden S; Neels JG; Churchill MJ; Dawson P; Ołdziej S; Jagielska A; Scheraga HA; Loskutoff DJ; Dyson HJ
Biochemistry; 2004 Jun; 43(21):6519-34. PubMed ID: 15157085
[TBL] [Abstract][Full Text] [Related]
9. Different structural requirements for plasminogen activator inhibitor 1 (PAI-1) during latency transition and proteinase inhibition as evidenced by phage-displayed hypermutated PAI-1 libraries.
Stoop AA; Eldering E; Dafforn TR; Read RJ; Pannekoek H
J Mol Biol; 2001 Jan; 305(4):773-83. PubMed ID: 11162091
[TBL] [Abstract][Full Text] [Related]
10. Localization of a vitronectin binding region of plasminogen activator inhibitor-1.
Padmanabhan J; Sane DC
Thromb Haemost; 1995 May; 73(5):829-34. PubMed ID: 7482411
[TBL] [Abstract][Full Text] [Related]
11. Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivation.
Nar H; Bauer M; Stassen JM; Lang D; Gils A; Declerck PJ
J Mol Biol; 2000 Mar; 297(3):683-95. PubMed ID: 10731421
[TBL] [Abstract][Full Text] [Related]
12. Vitronectin inhibits plasminogen activator inhibitor-1-induced signalling and chemotaxis by blocking plasminogen activator inhibitor-1 binding to the low-density lipoprotein receptor-related protein.
Kamikubo Y; Neels JG; Degryse B
Int J Biochem Cell Biol; 2009 Mar; 41(3):578-85. PubMed ID: 18703159
[TBL] [Abstract][Full Text] [Related]
13. Wound-induced migration of MDA-MB-435 and SKOV-3 cancer cells is regulated by plasminogen activator inhibitor-1.
Whitley BR; Church FC
Int J Oncol; 2005 Sep; 27(3):749-57. PubMed ID: 16077925
[TBL] [Abstract][Full Text] [Related]
14. Copper(II) Ions Increase Plasminogen Activator Inhibitor Type 1 Dynamics in Key Structural Regions That Govern Stability.
Bucci JC; Trelle MB; McClintock CS; Qureshi T; Jørgensen TJ; Peterson CB
Biochemistry; 2016 Aug; 55(31):4386-98. PubMed ID: 27416303
[TBL] [Abstract][Full Text] [Related]
15. Less pronounced enhancement of thrombin-dependent inactivation of plasminogen activator inhibitor type 1 by low molecular weight heparin compared with unfractionated heparin.
Nakamura R; Umemura K; Hashimmoto H; Urano T
Thromb Haemost; 2006 Apr; 95(4):637-42. PubMed ID: 16601834
[TBL] [Abstract][Full Text] [Related]
16. A method for defining binding sites involved in protein-protein interactions: analysis of the binding of plasminogen activator inhibitor 1 to the somatomedin domain of vitronectin.
Royle G; Deng G; Seiffert D; Loskutoff DJ
Anal Biochem; 2001 Sep; 296(2):245-53. PubMed ID: 11554720
[TBL] [Abstract][Full Text] [Related]
17. The structural basis for the pathophysiological relevance of PAI-I in cardiovascular diseases and the development of potential PAI-I inhibitors.
Gils A; Declerck PJ
Thromb Haemost; 2004 Mar; 91(3):425-37. PubMed ID: 14983217
[TBL] [Abstract][Full Text] [Related]
18. Hydrogen/deuterium exchange mass spectrometry reveals specific changes in the local flexibility of plasminogen activator inhibitor 1 upon binding to the somatomedin B domain of vitronectin.
Trelle MB; Hirschberg D; Jansson A; Ploug M; Roepstorff P; Andreasen PA; Jørgensen TJ
Biochemistry; 2012 Oct; 51(41):8256-66. PubMed ID: 22957734
[TBL] [Abstract][Full Text] [Related]
19. Recombinant plasminogen activator inhibitor type 1: a review of structural, functional, and biological aspects.
Reilly TM; Mousa SA; Seetharam R; Racanelli AL
Blood Coagul Fibrinolysis; 1994 Feb; 5(1):73-81. PubMed ID: 8180342
[TBL] [Abstract][Full Text] [Related]
20. The composition of complexes between plasminogen activator inhibitor 1, vitronectin and either thrombin or tissue-type plasminogen activator.
van Meijer M; Stoop A; Smilde A; Preissner KT; van Zonneveld AJ; Pannekoek H
Thromb Haemost; 1997 Mar; 77(3):516-21. PubMed ID: 9066004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
